Physician profile
Neil J Maki
NPI 1841287968
$619,959.54
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.16 · 2020: $548K · 2021: $219 · 2022: $72K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Anika Therapeutics, INC. | $619,442.68 | 2020-2022 | |
| Encore Medical, Lp | $136.80 | 2022 | |
| Zimmer Biomet Holdings, INC. | $101.19 | 2021 | |
| Exactech, INC. | $75.22 | 2021 | |
| Depuy Synthes Sales INC. | $71.04 | 2019-2021 | |
| Ormco Corporation | $29.82 | 2020 | |
| Sanofi-Aventis U.S. LLC | $27.97 | 2019 | |
| Stryker Corporation | $26.76 | 2022 | |
| Pacira Therapeutics, INC. | $17.34 | 2019 | |
| Baudax Bio INC. | $16.57 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $14.15 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$1,628,233.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Maki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.